1. Home
  2. VZLA vs MPLT Comparison

VZLA vs MPLT Comparison

Compare VZLA & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VZLA

Vizsla Silver Corp.

HOLD

Current Price

$3.35

Market Cap

1.2B

Sector

N/A

ML Signal

HOLD

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$28.64

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VZLA
MPLT
Founded
2017
2018
Country
Canada
United States
Employees
N/A
133
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
VZLA
MPLT
Price
$3.35
$28.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$7.00
$32.67
AVG Volume (30 Days)
6.4M
343.3K
Earning Date
12-12-2025
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.82
$12.24
52 Week High
$7.19
$33.28

Technical Indicators

Market Signals
Indicator
VZLA
MPLT
Relative Strength Index (RSI) 43.86 51.36
Support Level $3.15 $26.07
Resistance Level $4.13 $31.69
Average True Range (ATR) 0.22 2.55
MACD -0.02 -0.01
Stochastic Oscillator 22.91 58.70

Price Performance

Historical Comparison
VZLA
MPLT

About VZLA Vizsla Silver Corp.

Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: